Abstract |
There are no data available on the risk of extrapyramidal symptoms when using long-term flupenthixol in low dosage in patients suffering from anxiety and depressive disorders. In a case control study 106 patients essentially treated with the neuroleptic flupenthixol in a so-called low, non- antipsychotic dosage were compared to n=37 otherwise comparable patients who never had been treated with neuroleptics. The investigator was blind to the previous treatment conditions. Extrapyramidal symptoms were found although with a low prevalence and mild degree: 6.7% tardive dyskinesia, none in controls; pseudoparkinsonism 26%, 16% in controls. Extrapyramidal side-effects, especially tardive dyskinesia, have to be considered in the individual weighing of therapeutic benefits and risks even when prescribing flupenthixol in low dosages.
|
Authors | J Fritze, I Spreda |
Journal | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
(Eur Neuropsychopharmacol)
Vol. 7
Issue 4
Pg. 261-6
(Nov 1997)
ISSN: 0924-977X [Print] Netherlands |
PMID | 9443657
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Antipsychotic Agents
- flupenthixol decanoate
- Flupenthixol
|
Topics |
- Adult
- Antipsychotic Agents
(administration & dosage, adverse effects)
- Anxiety Disorders
(drug therapy)
- Case-Control Studies
- Depressive Disorder
(drug therapy)
- Dyskinesia, Drug-Induced
(etiology)
- Female
- Flupenthixol
(administration & dosage, adverse effects, analogs & derivatives)
- Germany
- Humans
- Male
- Middle Aged
- Parkinson Disease, Secondary
(chemically induced)
|